Effects of cefotaxime single administration and of cefotaxime + fosfomycin administration against respiratory tract infections
Shimokata, K.; Torigai, K.; Kato, M.; Sakai, S.; Nomura, F.; Ito, T.; Saka, H.; Senda, Y.; Torii, Y.; Ito, T.
Japanese Journal of Antibiotics 41(9): 1261-1271
1988
ISSN/ISBN: 0368-2781 PMID: 3071617 Document Number: 305736
Subjects in a cefotaxime (CTX) single administration group and in a CTX + fosfomycin (FOM) administration group were randomly selected for a comparative study on the utility of each product against respiratory tract infections. Overall improvement rates were 81.3% in 32 cases of the CTX single administration group, and 75.6% in 41 cases of the CTX + FOM concomitant administration group. No statistical difference was observed. As for adverse reactions and abnormal laboratory test results, pyrexia, thrombocytopenia, increases in GOT and GPT, and increase in GPT were observed in 4 cases of the CTX single administration group, while angialgia, increases in GOT and GPT (3 cases), and increases in BUN, (totalling 5), were observed in the CTX + FOM group. However, all the symptoms were transient, and none was serious in nature.